ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NCAB Opposes Line Item for Centers

May 23, 1980

AACR settles dispute with Toronto Convention Center and hotels over cancellation of 2003 annual meeting. Travelers Insurance covered AACR’s claim.

April 15, 2005

Program Announcement For Clinical Research

February 29, 1980

NCI Clinical Trials Working Group is looking for pragmatic solutions to improve cancer clinical trials system, Institute official says.

September 24, 2004

Funding Opportunity: Stand Up To Cancer Canada to Fund Two Dream Teams

October 17, 2014

Chart of FY 1991 Budget For NCI By Mechanism

February 2, 1990